The high authority for health (HA) recommended this Friday, May 9 to favor in the future certain anti -proven vaccines among the oldest, marking a change of doctrine after a particularly violent epidemic.
“They recommend them as part of the seasonal flu vaccination strategy, in people 65 years of age or older, that Efluelda and Flow vaccines are preferably used compared to available dose vaccines available,” the institution said in a press release.
Efluelda, produced by the giant healthy, and flow, by the Vifor laboratory, are vaccines designed to be more effective. The first is more dosed in antigens, the components of the virus that the immune system learns to recognize, while the second includes an adjuvant, that is, a component destined to strengthen its action.
Controversy between laboratories and health authorities
However, these two vaccines, in particular Efluelda, have been the origin of a controversy between laboratories and health authorities for several years. Until then, they did not judge that they had a convincing interest in relation to other vaccines and, therefore, did not recommend them more than the others.
Due to this situation, Sanofi had not marketed his effluelda vaccine this season, considering the price that the authorities offered him too low.
Since then, the 2024/2025 epidemic of influenza has proven to be particularly violent, with a high mortality of previous years, which should review its position, especially because vaccines in circulation testified only to limited efficiency in the elderly.
He explained that he has “taken into account the new data in the literature that show the capacity of these two vaccines”, Efluelda and Fluad “, to reduce the number of hospitalizations in the elderly, as well as the number of influenza experienced in the laboratory”, evaluating their efficiency gain with standard vaccines to 15-25%.
Therefore, they recommend them mainly in those over 65, the main category of people led by anti-writing vaccination campaigns. On the other hand, he has refrained from elaborating a hierarchy between efluelda and flow, and therefore does not recommend one instead of another.
Therefore, this position opens the way to a return from Efluelda to the market, even if it will still be necessary to wait for a new opinion about the reimbursement conditions, then a resumption of negotiations about its price.
Source: BFM TV
